A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 161-167

  Liu, Mu En ^a,b   Liao, Yi Chu ^c,d   Lin, Ruey Tay ^e,f   Wang, Yung Song ^a,e   Hsi, Edward ^e,f   Lin, Hsiu Fen ^e,f   Chen, Ku Chung ^a,g   Juo, Suh Hang H ^a,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atherosclerosis; Intima media thickness; MicroRNAs; SNP; Stroke

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; MICRORNA; MICRORNA 616; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN ISCHEMIA; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; EMBRYO; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; BRAIN ISCHEMIA; CAROTID ARTERY DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE;

EID: 84876799363     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.036     Document Type: Article

References (40)

1. Bak S., Gaist D., Sindrup S.H., et al. Genetic liability in stroke: a long-term follow-up study of Danish twins. Stroke; a Journal of Cerebral Circulation 2002, 33:769-774.
2. Della-Morte D., Guadagni F., Palmirotta R., et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. Pharmacogenomics 2012, 13:595-613.
3. Jousilahti P., Rastenyte D., Tuomilehto J., et al. Parental history of cardiovascular disease and risk of stroke. A prospective follow-up of 14,371 middle-aged men and women in Finland. Stroke; a Journal of Cerebral Circulation 1997, 28:1361-1366.
4. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. The New England Journal of Medicine 1999, 340:14-22.
5. Fox C.S., Polak J.F., Chazaro I., et al. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke; a Journal of Cerebral Circulation 2003, 34:397-401.
6. Juo S.H., Lin H.F., Rundek T., et al. Genetic and environmental contributions to carotid intima-media thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke; a Journal of Cerebral Circulation 2004, 35:2243-2247.
7. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
8. Chen K.C., Juo S.H. microRNAs in atherosclerosis. The Kaohsiung Journal of Medical Sciences 2012, 28:631-640.
9. Chen K.C., Hsieh I.C., Hsi E., et al. Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. Journal of Cell Science 2011, 124:4115-4124.
10. Chen K.C., Liao Y.C., Hsieh I.C., et al. OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: novel mechanisms for cardiovascular diseases. Journal of Molecular and Cellular Cardiology 2012, 52:587-595.
11. Bernig T., Chanock S.J. Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Review of Molecular Diagnostics 2006, 6:319-331.
12. Brodersen P., Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nature Reviews Molecular Cell Biology 2009, 10:141-148.
13. Mishra P.J., Humeniuk R., Mishra P.J., et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:13513-13518.
14. Sethupathy P., Collins F.S. MicroRNA target site polymorphisms and human disease. Trends in Genetics: TIG 2008, 24:489-497.
15. Liang C.L., Hsi E., Chen K.C., et al. A functional polymorphism at 3'UTR of the PAX6 gene may confer risk for extreme myopia in the Chinese. Investigative Ophthalmology & Visual Science 2011, 52:3500-3505.
16. Chen K.C., Hsi E., Hu C.Y., et al. MicroRNA-328 may influence myopia development by mediating the PAX6 gene. Investigative Ophthalmology & Visual Science 2012, 53:2732-2739.
17. WHO MONICA Project PI The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. Journal of Clinical Epidemiology 1988, 41:105-114.
18. Yang H.C., Lin C.H., Hsu C.L., et al. A comparison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians. Journal of Biomedical Science 2006, 13:489-498.
19. Wendelhag I., Liang Q., Gustavsson T., et al. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke; a Journal of Cerebral Circulation 1997, 28:2195-2200.
20. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radical Research 2000, 33(Suppl.):S85-S97.
21. Mackness M.I., Mackness B., Durrington P.N., et al. Paraoxonase and coronary heart disease. Current Opinion in Lipidology 1998, 9:319-324.
22. Can Demirdogen B., Turkanoglu A., Bek S., et al. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke. Clinical Biochemistry 2008, 41:1-9.
23. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arteriosclerosis Thrombosis and Vascular Biology 2001, 21:1451-1457.
24. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
25. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
26. Shih D.M., Xia Y.R., Wang X.P., et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. The Journal of Biological Chemistry 2000, 275:17527-17535.
27. Oda M.N., Bielicki J.K., Ho T.T., et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochemical and Biophysical Research Communications 2002, 290:921-927.
28. Marsillach J., Camps J., Beltran-Debón R., et al. Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. European Journal of Clinical Investigation 2011, 41:308-314.
29. Perła-Kaján J., Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012, 43:1405-1417.
30. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. American Journal of Human Genetics 1983, 35:1126-1138.
31. Leviev I., Negro F., James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arteriosclerosis Thrombosis and Vascular Biology 1997, 17:2935-2939.
32. Brophy V.H., Jampsa R.L., Clendenning J.B., et al. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. American Journal of Human Genetics 2001, 68:1428-1436.
33. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis Thrombosis and Vascular Biology 2000, 20:516-521.
34. Wheeler J.G., Keavney B.D., Watkins H., et al. Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 2004, 363:689-695.
35. Imai Y., Morita H., Kurihara H., et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000, 149:435-442.
36. Roest M., Jansen A.C., Barendrecht A., et al. Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clinical Biochemistry 2005, 38:123-127.
37. Srinivasan S.R., Li S., Chen W., et al. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. Atherosclerosis 2004, 177:167-174.
38. Vickers K.C., Palmisano B.T., Shoucri B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature Cell Biology 2011, 13:423-433.
39. Leeper N.J., Raiesdana A., Kojima Y., et al. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. Journal of Cellular Physiology 2011, 226:1035-1043.
40. Raitoharju E., Lyytikäinen L.P., Levula M., et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011, 219:211-217.